Serum brain-derived neurotrophic factor levels at 6 months after remission are not associated with subsequent depressive episodes.
Serum brain-derived neurotrophic factor levels at 6 months after remission are not associated with subsequent depressive episodes.
复制标题
缓解后 6 个月的血清脑源性神经营养因子水平与随后的抑郁发作无关。
DOI：
10.1097/01.jcp.0000426188.19174.a2
复制
发表时间：
2012
影响因子：
2.9
通讯作者：
J. Nakamura
中科院分区：
文献类型：
--
作者：
R. Yoshimura;H. Hori;Atsuko Sugita;W. Umene‐Nakano;A. Katsuki;J. Nakamura
讨论 最有趣的发现是抑郁状态复发前的血清 BDNF 水平没有变化。从缓解到复发的平均 (SD) 持续时间为 4.3 (1.4) 个月（最短 1 个月；最长 6 个月）。复发前的血清 BDNF 水平在大约 4 个月（6 个月采样）时没有下降，平均在 10 个月时出现下降。简而言之，最新的血清 BDNF 水平并不能预测复发。我们之前证明了 HAMD17 评分与血浆 BDNF 水平之间存在负相关。 8 我们在本研究中使用较小的样本再次证实了之前关于血清 BDNF 水平与 HAMD17 评分之间相关性的发现。总而言之，这些发现表明血清 BDNF 水平是抑郁状态严重程度的候选生物标志物。然而，从这些发现来看，尚不清楚血清 BDNF 变化在什么时候开始伴随抑郁状态。原因之一是本研究的所有参与者都服用了抗抑郁药物，这会增加血清 BDNF 水平。 9 简而言之，监测血清 BDNF 水平来预测复发可能毫无用处，尤其是对于服用抗抑郁药物的患者。先前的一项研究表明，测量 proBDNF 是有帮助的，它是成熟 BDNF 的前体，与长期抑郁有关，并且还抑制树突棘生长 10 和成熟 BDNF。总之，血清 BDNF 水平反映了重度抑郁症患者并发的抑郁状态，而不是预测这些水平下降，而随后抑郁发作的复发与缓解后 6 个月时的血清 BDNF 水平无关。
DISCUSSIONThe most interesting finding was that serum BDNF levels before relapse of depressive states were not changed. The mean (SD) duration from remission to relapse was 4.3 (1.4) months (minimum, 1 month; maximum, 6 months). Serum BDNF levels were not decreased at the roughly 4-month mark (the 6-month sampling) before relapse, which occurred on average at 10 months. In short, the up-to-date serum BDNF level is not a predictor of relapse. We previously demonstrated a negative correlation between the HAMD17 score and plasma BDNF levels. 8 We reconfirmed our previous finding in correlation between serum BDNF levels and HAMD17 scores using a smaller sample in the present study. Taken together, these findings suggest that serum BDNF levels are a candidate biomarker for the severity of depressive state. From these findings, however, it remains unclear at what point the onset of changes in serum BDNF is accompanied by a depressive state. One of the reasons is that all participants in the present study were administered antidepressants, which increase serum BDNF levels. 9 In short, monitoring serum BDNF levels for predicting relapse might be useless, especially in patients taking antidepressant drugs. A previous study suggests that it is helpful to measure proBDNF, which is a precursor of mature BDNF and is associated with long-term depression and also suppresses dendritic spine growth 10 and mature BDNF. In conclusion, serum BDNF levels reflect concurrent depressive state in patients with major depressive disorder rather than predict that those levels decline, whereas subsequent relapse in depressive episodes is not associated with serum BDNF levels at 6 months after remission.